PLXP: PLx Pharma Inc. - Summary | Jitta

PLx Pharma Inc.

NASDAQ:PLXP

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.00
Loss Chance
58.4%
0.68JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (21)
Recent Business Performance (28)
Financial Strength (35)
Return to Shareholders (4)
Competitive Advantage (16)
Jitta Signs
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2021
Operating MarginInconsistent
Recent Business PerformanceEarning decline 56.90% in the last year
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
0.68
100.00%
3.03
208.13%
3.05
162.56%
Pharmaceuticals
5.41
69.27%
2.33
16.57%
5.69
90.01%
COMPANY DESCRIPTION
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.